{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-039644","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.032901+00:00","generated_at":"2026-06-02T23:20:42.745321+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CERO Therapeutics receives Nasdaq deficiency notice for MVLS below $50M; 180-day cure period","bullets":["May 2, 2024 Nasdaq letter: CERO's common stock MVLS below $50M for 30 consecutive days.","Company has until Oct 29, 2024 to regain compliance by closing at MVLS >= $50M for 10 consecutive days.","If non-compliant, may transfer to Nasdaq Capital Market or face delisting proceedings.","Company says it will monitor MVLS and evaluate options to regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-039644","json":"https://secwatch.observer/filing/0001213900-24-039644.json","markdown":"https://secwatch.observer/filing/0001213900-24-039644.md","text":"https://secwatch.observer/filing/0001213900-24-039644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024039644/0001213900-24-039644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024039644/ea0205239-8k_cerotherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:20:42.745321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2208a92c4265f384aa436ad68cf60ac92d9a845","claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).","evidence_excerpt":"May 2, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024039644/0001213900-24-039644-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5450(b)(2)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}